ASH 2022 Conference Coverage
ASH 2022 Results From the Phase 2 OUTREACH Study: Lisocabtagene Maraleucel Administered as Outpatient/Inpatient Treatment in the Community/Non-University Setting in Patients With R/R LBCL
By
ASH 2022 Conference Coverage
FEATURING
Yuliya Linhares
By
ASH 2022 Conference Coverage
FEATURING
Yuliya Linhares
Login to view comments.
Click here to Login